スコットランドで隔離されたゴノコックスのシプロフロクサシン耐性の増加
Lancet (London, England)
|December 29, 2000
まとめ
スコットランドでは,シプロフロクサシンに対するネッセリア・ゴノレアの耐性が増加しています. この傾向により,シプロフロキサシンは,ゴノコック感染症の主要な治療法としてすぐに不適当になる可能性があります.
科学分野:
- 微生物学 微生物学とは
- 抗生物質耐性菌は,抗生物質耐性菌として存在します.
- 公衆衛生は公衆衛生である.
背景:
- この研究では,スコットランドで1991年から1999年の間に発生した4415例のネイセリア・ゴノレア感染症の感受性データを検討した.
- それはシプロフロクサシン最小抑制濃度 (MIC) 値の変化に焦点を当てた.
研究 の 目的:
- スコットランドのネイセリア・ゴノレア菌の孤立体におけるシプロフロクサシン感受性の傾向を分析する.
- 淋病の治療に対する抵抗性の増大の臨床的影響を評価する.
主な方法:
- スコットランドの4415例の感染 (1991年-1999年) のネイセリア・ゴノレア菌単離物の遡及的レビュー.
- シプロフロクサシン最小抑制濃度 (MIC) を各単離体ごとに決定する.
- 感受性の傾向と耐性比率の統計的分析.
主要な成果:
- シプロフロクサシン感受性の低下 (MIC ≥0.05 mg/L) を有する単離物の割合は,1991年の0.5%から1999年の5%に増加した (p<0.001).
- 1999年の臨床耐性 (MIC ≥1 mg/L) は,それ以前の4年間の平均値 (0.9%,p=0.02) と比べて,著しく高かった (2,2%).
結論:
- スコットランドのニセリア・ゴノレア菌の単離体の中でシプロフロクサシン耐性の有意な増加が観察されました.
- 耐性の継続的な上昇は,第一線性淋病治療としてのシプロフロクサシンの有用性を損なう可能性があります.
- 緊急のモニタリングと潜在的な治療戦略の再評価が必要である.
さらに関連する動画
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
関連する概念動画
Antibiotic Selection
Overview
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
